Overview

Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI)

Status:
Completed

Trial end date:
2007-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and efficacy of Ultrase® MT20 compared to placebo for the correction of fat and protein malabsorption in participants with cystic fibrosis (CF) and exocrine pancreatic insufficiency (EPI). This study is sponsored by Aptalis Pharma (formerly Axcan).

Phase:

Phase 3

Details

Lead Sponsor:

Forest Laboratories

Treatments:

Pancreatin
Pancrelipase